72.11.Z - Scientific research and development activities
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
32 - Other manufacturing of products
72 - Scientific research and development activities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Assets | 12,3 | 12,2 | 13,5 | 10,7 |
Gross profit (loss) | -1,2 | -2,1 | -5,4 | -157,5 |
EBITDA | -1,2 | -1,8 | -4,7 | -162 |
Net profit (loss) | -1,2 | -2,1 | -5,4 | -157,5 |
Cash | 12 | 8,4 | 8 | -4,5 |
Net income from sale | 0 | 0 | -∞ | |
Liabilities and provisions for liabilities | 3,4 | 5,1 | 8,3 | 62,2 |
Short time liabilities | 0,5 | 1,6 | 1,7 | 10,5 |
Working assets | 12,3 | 9,7 | 8,4 | -12,7 |
Equity capital | 8,9 | 7,1 | 5,2 | -26,8 |
Operating profit (EBIT) | -1,2 | -2,1 | -5,2 | -150,1 |
Depreciation | 0 | 0,3 | 0,5 | 77,8 |
% | % | % | p.p. | |
Profitability of capital | -13,4 | -29,6 | -104,1 | -74,5 |
Equity capital to total assets | 72,3 | 57,9 | 38,3 | -19,6 |
Gross profit margin | -598 169,1 | |||
EBITDA Margin | -522 921,8 | |||
Days | Days | Days | Days | |
Short term commitment turnover cycle | 2 147 483 648 | 700 363 | -2 146 783 285 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane